Group 1 - The stock price of Zhaoxin Biopharmaceuticals (02509.HK) has shown volatility over the past week, with an overall downward trend, closing at HKD 19.33 on February 13, 2026, down 2.37% for the day [1] - The stock experienced a trading range of 10.03% over the past five days, with a total trading volume of approximately HKD 16.88 million, indicating increased market activity [1] - Technical indicators suggest short-term price pressure, with the MACD histogram remaining negative and the KDJ J-line dropping to 7.39 [1] Group 2 - Matrix Life Vision's report on February 12, 2026, highlights Zhaoxin Biopharmaceuticals as a biotech company focused on autoimmune and allergic diseases, with key products like QX005N (IL-4Rα monoclonal antibody) and QX002N (IL-17A monoclonal antibody) in late-stage clinical trials [2] - The report notes that while the company faces intense competition and clinical failure risks, its long-term growth potential hinges on the commercialization progress of its core products [2] - In the first half of 2025, the company reported a significant revenue increase of 359.69% to HKD 206 million, with losses narrowing by 83.11%, indicating a strong cash flow situation to support R&D [2]